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Cohort profile
AbstrACt
Purpose The linked prescriptions cancer registry data 
resource was set up to extend our understanding of the 
pathway for patients with cancer past secondary care into 
the community, to ultimately improve patient outcomes.
Participants The linked prescriptions cancer registry 
data resource is currently available for April to July 2015, 
for all patients diagnosed with cancer in England with a 
dispensed prescription in that time frame. The dispensed 
prescriptions data are collected by National Health Service 
(NHS) Prescription Services, and the cancer registry data 
are processed by Public Health England. All data are 
routine healthcare data, used for secondary purposes, 
linked using a pseudonymised version of the patient’s 
NHS number and date of birth. Detailed demographic 
and clinical information on the type of cancer diagnosed 
and treatment is collected by the cancer registry. The 
dispensed prescriptions data contain basic demographic 
information, geography measures of the dispensed 
prescription, drug information (quantity, strength and 
presentation), cost of the drug and the date that the 
dispensed prescription was submitted to NHS Business 
Services Authority.
Findings to date Findings include a study of end of 
life prescribing in the community among patients with 
cancer, an investigation of repeat prescriptions to derive 
measures of prior morbidity status in patients with cancer 
and studies of prescription activity surrounding the date of 
cancer diagnosis.
Future plans This English linked resource could be used 
for cancer epidemiological studies of diagnostic pathways, 
health outcomes and inequalities; to establish primary care 
comorbidity indices and for guideline concordance studies 
of treatment, particularly hormonal therapy, as a major 
treatment modality for breast and prostate cancer which 
has been largely delivered in the community setting for a 
number of years.
IntroduCtIon 
National healthcare systems make it more 
feasible to routinely collect detailed health-
care data for the entire population, which 
are vital for population health research. For 
example, in the National Health Service 
(NHS) in England, Public Health England 
(PHE) holds cancer and other disease data; 
NHS Digital collects hospital activity1 and 
other process data, while the NHS Busi-
ness Services Authority (NHSBSA) gathers 
administrative data for payments of services. 
NHSBSA gathers this through NHS Prescrip-
tion Services, which calculates the remunera-
tion and reimbursement owed to dispensing 
pharmacy contractors in the community 
across England, as per the Drug Tariff.2 
The resulting data resource collected by 
NHSBSA is vast. Over one billion prescrip-
tion items were dispensed in England in 
2014, an increase of over 55% since 2004 at a 
cost of nearly £9 billion per year.3 As in many 
developed countries, prescribing rates have 
strengths and limitations of this study
 ► The linkage of community-dispensed prescriptions 
data to cancer registration data can greatly enhance 
our understanding of the patient pathway, as it can 
provide novel insight into symptom profiles and 
potentially identify patterns which could indicate 
opportunities for the earlier diagnosis of cancer.
 ► The key strength of this data source is its 
population  coverage, and the pseudonymisation 
process strengthens its value, as it has permitted 
the existence of an anonymised national control 
population for comparison purposes, to understand 
how patients with cancer differ from the general 
population.
 ► Sex is not available in the prescriptions data, 
therefore cannot be used to match controls of 
non-cancer patients.
 ► The indication for the dispensed drug is not included 
in the data which may be problematic for drugs with 
multiple indications, for example, antidepressants 
can be indicated for depression or chronic pain.
 ► For pharmacovigilance studies, one should be aware 
that dispensed drug information does not guarantee 
that the patient has taken the medication.
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continued to rise in England, largely due to an increas-
ingly old and multimorbid population.4 Therefore, the 
importance of collecting and using such data is increasing.
Since April 2015, NHSBSA expanded the dataset to 
include NHS number, which is the primary patient iden-
tifier in England. This has transformed the data, allowing 
linkage to other health data, for example, national cancer 
registration data.
The National Cancer Registration and Analysis Service 
(NCRAS) in PHE is responsible for collecting data on all 
cases of cancer and certain benign tumours that occur in 
people living in England.5 Hospital trusts submit multiple 
feeds of electronic health data, which are processed and 
combined by trained registration officers into a clinically 
comprehensive record for each tumour. The majority of 
cancer care is delivered in secondary care; therefore, the 
data collected reflect this.
A Data Sharing Agreement was established between 
PHE and NHSBSA, for NHSBSA to supply pseudony-
mised dispensed prescriptions data to PHE, providing 
hitherto missing information on this aspect of community 
healthcare for patients with cancer. We aim to describe 
the dispensed prescriptions data, the linkage and key data 
quality implications, with a focus on the linked data avail-
able within PHE.
Cohort desCrIPtIon
data collected
The dispensed prescriptions data are collected from 
the Electronic Prescribing Service (EPS) and captured 
from the paper FP10 prescription forms using high 
speed scanners and character recognition software, with 
human input when required. FP10 forms are the legal 
prescription forms issued to patients in England, which 
they take to their chosen pharmacy. As of summer 2017, 
over half of the prescriptions dispensed in the commu-
nity in England were issued via the EPS service.6 This 
has increased since 2015. Both EPS and FP10 forms 
are legal prescriptions, which are usually issued by a 
doctor, but may also be issued by a nurse, pharmacist 
prescriber or supplementary prescriber. The data are 
collected from prescriptions dispensed at a commu-
nity pharmacy. Prescriptions are not filled at commu-
nity pharmacies in the following scenarios: drugs 
supplied during a hospital stay, including those filled at 
discharge; drugs provided by private healthcare institu-
tions; drugs supplied during a stay at a hospice or drugs 
supplied by other healthcare institutions, for example, 
urgent care centres.
Demographic, prescriber and drug details are collected 
for the dispensed prescriptions, including quantity, 
strength (dose) and presentation (tablet, injection etc). 
The full drug item is recorded as per the British National 
Formulary (BNF) V.68.7 Exemptions to this classification 
are detailed in the BNF Classification booklet published 
by NHSBSA,8 including additional items not covered by 
the BNF, for example, dressings and appliances. A full 
data dictionary is shown in table 1, with the percentage 
completeness for each data item.
Dispensed prescriptions data are available from April 
2015, with data for April to July 2015 currently linked to 
cancer registration data. Data from August 2015 onwards 
will be available in due course, with updated linked data 
available in 2018. The objective is to link updated prescrip-
tions data to the cancer registry data on a quarterly basis, 
with an approximate lag to real time of 6 months. During 
April to July, 332 655 118 dispensed prescription items 
among 29 481 344 individuals are identified. Ten per 
cent of the dispensed items and 6% of the individuals 
were linked to the cancer registry data, and therefore 
had a history of cancer (restricting to malignant tumours 
excluding non-melanoma skin cancer [ICD-10 (Interna-
tional Statistical Classification of Diseases and Related 
Health Problems 10th Revision) C00-C97 excl. C44] diag-
nosed after 1994). Using this linked data, 90 840 patients 
were identified as being diagnosed with a malignant 
tumour during April to July 2015, and had a prescription 
dispensed during the same period. Among this cohort, 
99% of their dispensed prescriptions were issued by a 
General Practitioner (GP) practice9 (see table 2).
Pseudonymisation process
The partnership between NCRAS and NHSBSA has 
allowed NCRAS to obtain prescribing dispensed in 
the community information for both patients with and 
without cancer. The information on (anonymous) individ-
uals without cancer can be used for analytical purposes as 
‘controls’. It was required to be in an anonymised format 
because NCRAS does not have the legal permissions to 
hold identifiable data on patients without a cancer diag-
nosis. Therefore, a secure pseudonymisation process was 
developed within NCRAS to allow the data linkage to 
be performed securely, without requiring the individual 
identities of patients to be shared.
The stages performed by both NHSBSA and NCRAS of 
the data extraction, pseudonymisation and linkage are 
detailed in figure 1. The pseudonymisation procedure was 
run at source by NHSBSA on the dispensed prescriptions 
data, and the pseudonymised data were sent to NCRAS 
on an encrypted disk. The same pseudonymisation proce-
dure was also run by NCRAS on the identifiers of patients 
with cancer stored in the cancer registry. A script was then 
run which linked the pseudonymised dispensed prescrip-
tions data with patient records in the cancer registry 
using the pseudonym identifiers. A subset of the pseud-
onymised row-level dispensed prescriptions data linked to 
the cancer registry data was therefore securely created.
The pseudonymisation procedure uses standard third-
party encryption and hashing modules (a modified 
version of the OpenPseudonymiser approach10). Fields 
which identify a patient are encrypted (hashed), and 
these encrypted values replace the original. The fields 
used are a patient’s NHS number and their date of birth. 
The pseudonymisation procedure is run at source by 
NHSBSA on the prescriptions data. The procedure used 
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Table 1 Description of data items included, with data quality completeness of linked dispensed prescriptions cancer registry 
data, for patients diagnosed with malignant cancer (excluding non-melanoma skin cancer) after 1994 with a dispensed 
prescription record during April to July 2015 (n=1 680 764 patients and 33 669 294 prescription items)
Data item Description Completeness* (%)
Pseudonymised 
patient identifier
Code derived from patient NHS no and DOB
Month The month for which the claim for dispensed items has been submitted to NHSBSA. 100
Prescribed date The date on which the prescription item was prescribed and submitted to EPS by the prescriber 
organisation.
Note: only available for EPS messages
27
Prescribers postal 
code
The postal code of the prescribing practice, as held by the NHSBSA master database and the 
NHS Digital Organisation Data Service (ODS).
It is in text and numerical format as per standard postal codes.
27
Primary care 
organisation (PCO) 
code
The code allocated by ODS to the prescriber’s Clinical Commissioning Group or other PCO.
It is a five-digit code containing numbers and letters.
99.7
PCO name 100
Practice code The code of the general practice that carried out the prescribing, or other cost centre which 
is coded as a general practice in the NHSBSA master database. The code is allocated by 
NHSBSA.
It is a six-digit code containing numbers and letters.
>99.9
Practice name >99.9
Net ingredient cost This is the cost (in pence) of the dispensed item calculated from the reimbursement price held 
on the NHSBSA master database. The reimbursement price is the basic price for the quantity 
supplied of those drugs, appliances and chemical reagents as listed in parts VIII or IX of the 
Drug Tariff. For a drug not listed in part VIII, the price is normally determined by the list price 
published by the manufacturer, wholesaler or supplier of the pack size used for a prescription of 
that quantity.
100
Prescribed quantity A specific quantity prescribed of a drug or appliance.
Note: only available for EPS messages
100
No of items This shows the no of times a product appears on a prescription form or EPS message. 100
Unit of measure A description of the physical entity that can be handled, that is, tablet, ampoule, phial, mL. 
The unit of measure is held by the Dictionary of Medicines and Devices (dm+d) where this is 
appropriate to the product.
100
Pay quantity The quantity of a drug or appliance which the NHSBSA has reimbursed. Where the product is 
packed in a special container, the quantity may be expressed as the no of special containers 
dispensed.
100
Drug presentation 
paid
A description of the product reimbursed as held by the dm+d. Where this is an actual product, 
the description includes the name of the proprietary or generic item, along with the supplier/
manufacturer name. Where the product is a prescribable generic, the description of the generic 
product without supplier or trade name information is given.
Note: on many occasions this will be the same as that prescribed.
100
BNF code The NHSBSA database allocates BNF codes to drugs and medical devices: these codes are 
structured according to a series of hierarchical levels. Each level provides information about 
either the therapeutic use or pharmacological group of the drug or appliance. The structured 
coding is based on the BNF, with drug and appliance entries being arranged according to the 
BNF chapters, plus additional pseudo-chapters created by the NHSBSA.
>99.9
Patient age The age of the patient, in years, on the date the item was prescribed. 82
Exemption category The exemption category declared by the patient on the prescription form or included in the EPS 
message.
Where the age/DOB is computer generated on the prescription, this is used for age exemption 
purposes.
The exemption category declared by the patient on the prescription form (note that this can be 
completed in prescription items from EPS messages).
99
The exemption category included in the EPS message. 27
Indicator whether exemption category was declared by the patient on the prescription form or 
included in the EPS message.
100
*The number of dispensed prescription items with a known value as a percentage of all dispensed prescription items (both FP10 and EPS).
BNF, British National Formulary; DOB, date of birth; EPS, Electronic Prescribing Service; NHSBSA, NHS Business Services Authority; NHS, 
National Health Service.
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by both NHSBSA and NCRAS is identical. This allows us 
to match the pseudonyms in the dispensed prescriptions 
data, where possible, with those in the cancer registry 
without the need to reveal the original patient details. 
Current security technology shows that a ‘brute force’ 
approach could theoretically be used to decrypt the data, 
but in practice the probability is minuscule,11 therefore, 
in practice it is not possible to reidentify NHS numbers.
data quality
NHS Prescription Services reprocess a random sample 
of 50 000 dispensed prescription items a month to assess 
the accuracy of these data. As of December 2016, the 
processing accuracy was 99.5%.12
Preliminary analyses of the linked data highlighted a 
number of data quality issues. A number of these issues relate 
to the FP10 forms, which account for 73% of the items in 
the April to July 2015 data. In these items, the date informa-
tion is the month that the claim was submitted to NHSBSA, 
rather than the date that the drug was dispensed. There are 
therefore cases of inconsistent date orders, for example, the 
date of patient death is before the date of prescription for 
0.3% of dispensed prescription items. Among the FP10-dis-
pensed prescription items, age at prescription is missing for 
19% (in the unlinked data). However, the age at prescrip-
tion can be approximated for patients with cancer using 
the prescription date and date of birth of the patient (from 
cancer registration data). For patients without a missing age 
at prescription, this calculation highlighted inconsistencies 
for 0.2% of dispensed prescription items in the linked data. 
An inconsistency was defined as a difference in age of more 
than 1 year. Examples of this included a recorded age on 
the prescription record of 2 years, compared with a calcu-
lated age of 102 years.
NHSBSA processing of Electronic Transfer of Prescrip-
tions (ETP) messages has been interrupted on a small 
number of days and there are no dispensed prescriptions 
recorded for the first day in either April or May due to 
system downtime. A spike in the number of dispensed 
prescriptions exists at the end of each of the affected 
months, which could indicate a recording bias due to bulk 
processing of missed records. Another data quality issue is 
that the net ingredient cost for a particular drug can change 
each month, and assessments of cost must adjust for this; 
this field is present in both FP10 and EPS items.
Comparing the linked data to cancer registration 
data, there were systematic differences between the 
patients with cancer who were and were not dispensed 
a prescription. To demonstrate this, a cohort of 
patients diagnosed with malignant cancer (ICD-10: 
C00–C97, excluding C44), during April to July 2015 was 
identified. Among these 100 424 patients with cancer, 
90 840 patients received a prescription in the same 
time period (90%). The distribution of demographic 
and tumour factors, for example, age and cancer type, 
varied between patients with cancer with and without 
a dispensed prescription record in the same period 
(figure 2). The confidence intervals did not overlap for 
all but two factors; however, the absolute differences 
Table 2 Number of dispensed prescription items by the prescribing institution for a cohort of patients with cancer diagnosed 
during April to July 2015, with a prescription dispensed in the same time period
Prescribing setting from
NHS Digital’s GP practice list9
Dispensed
prescription items
Per cent of 
all dispensed 
prescription items
(%)
Per cent of prescription 
items dispensed by a 
listed practice9
(%)
GP practice 1 820 523 98.82 99.49
Out of hours practice 3806 0.21 0.21
Community health service 2810 0.15 0.15
Other 1106 0.06 0.06
Hospital service 456 0.02 0.02
Walk in centre practice 389 0.02 0.02
Urgent and emergency care 215 0.01 0.01
Hospice 168 0.01 0.01
Public health service 119 0.01 0.01
Walk in centre+out of hours practice 98 0.01 0.01
Care home/nursing home 95 0.01 0.01
Optometry service 8 0.00 0.00
Prison 6 0.00 0.00
Organisation not listed as a GP practice
by NHS Digital,9 assumed secondary care 12 396 0.67 –
Total 1 842 195 – – 
GP, general practitioner; NHS, National Health Service.
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were small. The most marked difference was for age at 
cancer diagnosis, where, for example, 49% of patients 
with cancer with a dispensed prescription were aged 
70–89, but among patients with cancer without a 
dispensed prescription only 18% were aged 70–89. Vari-
ation by age is expected clinically, as individuals often 
need treatment for an increasing number of conditions 
as they age (therefore the background rate changes), 
and patients with cancer who do not have any prescrip-
tions dispensed in the community may be particularly 
unwell and admitted to hospital. This highlights the 
need to control for age during analyses, particularly 
when matching to the general population. For sex, 
cancer site, stage at diagnosis and ethnicity, the abso-
lute differences were small (≤1.0).
Patient and public involvement
Patients and the public were not involved in the develop-
ment of this study. Data for this study are based on infor-
mation collected by the NHS.
Figure 1 Pseudonymisation and linkage process for the dispensed prescriptions data and cancer registry 
data. NCRAS, National Cancer Registration and Analysis Service; NHSBSA, NHS Business Services Authority.
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FIndIngs to dAte
Timely, record-level community-dispensed prescriptions 
data provide a rich data source for public health; espe-
cially when the coverage is national and near complete. 
The linkage of dispensed prescriptions data to national 
cancer registration data creates a powerful resource 
that facilitates a better understanding of healthcare use 
over the duration of illness. This may, to our knowl-
edge, become the largest resource of its kind globally, 
due to the underlying population size of England and 
longitudinal coverage of the national cancer registry. 
Projects of interest to NCRAS include a study of end of 
life prescribing in the community among patients with 
cancer, an investigation of repeat prescriptions to derive 
measures of prior morbidity status in patients with cancer 
and studies of prescription activity surrounding the date 
of cancer diagnosis.13 This work has not yet (as of March 
2018) been published in peer-reviewed journals.
A very similar resource is available in Scotland (the 
Prescribing Information System), and the existence of 
their unique numeric patient identifier allows linkage 
to other Scottish healthcare data, including the Scottish 
National Cancer Registry. The population size of Scotland 
is smaller than England, but the benefit of such a linked 
resource has been demonstrated.14 The national struc-
ture of healthcare in Denmark has also afforded a similar 
resource to be created, and epidemiological studies inves-
tigating the impact on early diagnosis have been recently 
emerging.15–17 This English linked resource could be used 
for cancer epidemiological studies of diagnostic pathways, 
health outcomes and inequalities; to establish primary 
care comorbidity indices and for guideline concordance 
studies of treatment. Hormonal therapy is one example 
of this, as it is a major treatment modality for breast and 
prostate cancer which has been largely delivered in the 
community setting for a number of years.
strengths And lImItAtIons
The linkage of community-dispensed prescriptions data 
to cancer registration data can greatly enhance our 
understanding of the patient pathway. It can provide 
novel insight into symptom profiles and improve our 
understanding of long-term trends in the patterns of 
drugs dispensed before and after a diagnosis of cancer 
(the latter of which may have utility as a proxy for quality 
of life). It could also potentially identify patterns which 
could indicate opportunities for the earlier diagnosis of 
cancer. The key strength of this data source is its popu-
lation coverage. Linkage to the cancer registration data 
also provides information on the date and cause of 
death of the patient, allowing effective censoring. This 
linked dispensed prescriptions and cancer registration 
data resource can also be linked to other datasets held 
by NCRAS, including Hospital Episodes Statistics,18 the 
Radiotherapy Dataset19 and the Systemic Anti-Cancer 
Figure 2 Representativeness of linked cancer registry and dispensed prescription data as compared with cancer registry 
data alone, by key patient and tumour characteristics (age at diagnosis, ethnicity, sex, tumour site and stage at cancer 
diagnosis). *Indicates non-overlapping confidence intervals.  
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Therapy dataset.20 The pseudonymisation process 
strengthens its value, as it has permitted the existence of 
an anonymised national control population for compar-
ison purposes, to understand how patients with cancer 
differ from the general population.
There are a number of limitations of this data resource, 
as with all routinely collected healthcare data.21 22 First, 
prescriptions dispensed in a private setting, prison setting 
or without an NHS number recorded are not captured by 
the data. However, the impact of this is estimated to be less 
than 3%,23 less than 1%24 25 and 10% of all prescriptions 
dispensed. In addition, prescriptions that were written 
but not dispensed, or not submitted by the pharmacy to 
NHS Prescription Services are not captured, though this is 
thought to be minimal as the dispenser would not be reim-
bursed. Sex is not captured within the dispensed prescrip-
tions dataset, neither is an alternative piece of information 
which could be used to derive sex (eg, title). This is only 
problematic for the control population, and limits the type 
of comparison that can be made.
The drug indication is not included in the prescription, 
therefore cannot be captured. For drugs with multiple indi-
cations, this may be problematic as it may be unclear which 
underlying condition required the prescription. To over-
come this, the patients’ prescribing history could be used to 
approximate the indication. Future work could link drugs 
prescribed to likely indications as recommended by the 
BNF. Ideally, the patient’s medical history, as recorded in 
primary care, would be available. However, a national data 
source of this has not been identified. Many primary care 
databases are available, for example, the Clinical Practice 
Research Datalink and The Health Improvement Network 
database, but these only cover 6.9%26 and 6.2%27 of the UK 
population, respectively.
The full date of the dispensed prescription and the 
prescribing organisations’ postal code is only available for 
dispensed prescriptions from the EPS. In the linked data 
(patients with cancer diagnosed after 1994), the propor-
tion of dispensed prescription items from FP10 forms, 
therefore without the day of prescription or prescribers’ 
postal code were 76% in April, 74% in May, 71% in June 
and 70% in July 2015, which is continually improving. The 
EPS is currently on phase 4 of deployment and release 2 of 
the system, with each phase improving the functionality for 
both GP practices and pharmacies, thereby improving ease 
of use. The latest statistics (as of 6 November 2017) showed 
that 91.6% of GP practices and 99.2% of pharmacies were 
using the EPS.6
Two further limitations exist, which are primarily rele-
vant for pharmacovigilance studies, particularly long-
term studies investigating whether a certain drug leads 
to cancer. Namely, the information captured is for drugs 
dispensed, irrespective of whether the patient actually 
took the drug. However, it can still be used as a proxy 
for an underlying disease or the presence of disease risk 
factor. Finally, for studies where detailed information on 
the strength of the drug is required, work must be under-
taken to parse text fields and accurately calculate the 
amount of active ingredient, using combinations of the 
data items available.
CollAborAtIon
The Data Sharing Agreement outlined the terms of the 
partnership, data transfer and subsequent use. These state 
that NHSBSA will remain the primary data owner for the 
prescriptions dataset and will continue to be responsible 
for the continuity, quality, timeliness and availability of 
the data it contains. PHE will assume the responsibility 
of in-common data controller as appropriate for all data 
transferred to it from the NHSBSA under the terms of the 
agreement. PHE will be responsible for determining and 
approving the specific purposes that fit within the objec-
tives of the agreed data exchange, for which the linked 
dispensed prescriptions and cancer registration dataset are 
used to support its statutory functions and core remit. PHE 
will be responsible for reviewing and approving the release 
of extracts of the linked data.
PHE has been granted specific legal permission to collect 
information about patients with cancer for specific purposes, 
without the need to seek consent. These purposes include 
health improvement and service provision. This permission 
was granted to PHE through Section 251 of the NHS Act 
2006. This support is reviewed annually by the Confiden-
tiality Advisory Group of the Health Research Authority.28 
PHE manages the release of potentially identifiable data 
through the Office for Data Release (ODR). The ODR 
provides a common governance framework for responding 
to requests to access PHE data, and is subject to strict confi-
dentiality provisions in line with the requirements of the 
Common Law Duty of Confidentiality,29 the Data Protec-
tion Act 199830 (to be superseded by the General Data 
Protection Regulation (EU) 2016/679 which will take effect 
on 25 May 2018)31 and the 7 Caldicott principles.32 Appli-
cations to access this linked prescriptions data for patients 
with cancer should be directed through the ODR,33 and 
application forms are available on their website.33
The ODR accepts applications from UK, EEA and inter-
national organisations; however, approvals to process any 
data controlled by PHE will be subject to adequate safe-
guards being established with the data recipient to ensure 
that: the level of protection afforded to individuals by UK 
data protection laws is not undermined; the purpose of any 
request complements the permissions to process the data 
without consent granted to PHE by the Secretary of State 
under the Health Service (Control of Patient Information) 
Regulations 200234 and that appropriate ethical assurances 
are met.
ConClusIons
The need to understand the healthcare of patients with 
cancer in the community is paramount, both following 
their diagnosis and to improve earlier diagnosis. Repur-
posing administrative datasets is an efficient method 
of doing this, providing the data quality and content is 
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sufficient. National sources of reimbursed prescriptions, 
such as the resource described in this profile, have been 
valuable to epidemiological research in Scandinavian 
countries, particularly Denmark.15–17 We have demon-
strated the value of dispensed prescriptions data for 
research and health monitoring in England, and the 
added value when linked to cancer registration infor-
mation. The long-term coverage of the national cancer 
registration data has created a large linked resource even 
with 4 months of dispensed prescriptions data, and with 
more months of data the scale of the resource will expand 
creating a resource of unparalleled scale. The implica-
tions of data quality must be considered when designing 
studies, but the value to cancer research is clear.
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